Global Herceptin (Trastuzumab) and Biosimilar Supply, Demand and Key Producers, 2023-2029
The global Herceptin (Trastuzumab) and Biosimilar market size is expected to reach $ 6357.7 million by 2029, rising at a market growth of 4.6% CAGR during the forecast period (2023-2029).
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.
This report studies the global Herceptin (Trastuzumab) and Biosimilar production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Herceptin (Trastuzumab) and Biosimilar, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Herceptin (Trastuzumab) and Biosimilar that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Herceptin (Trastuzumab) and Biosimilar total production and demand, 2018-2029, (K Units)
Global Herceptin (Trastuzumab) and Biosimilar total production value, 2018-2029, (USD Million)
Global Herceptin (Trastuzumab) and Biosimilar production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Herceptin (Trastuzumab) and Biosimilar consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Herceptin (Trastuzumab) and Biosimilar domestic production, consumption, key domestic manufacturers and share
Global Herceptin (Trastuzumab) and Biosimilar production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Herceptin (Trastuzumab) and Biosimilar production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Herceptin (Trastuzumab) and Biosimilar production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Herceptin (Trastuzumab) and Biosimilar market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, Pfizer, Organon, Teva and Viatris, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Herceptin (Trastuzumab) and Biosimilar market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Herceptin (Trastuzumab) and Biosimilar Market, By Region:
1. How big is the global Herceptin (Trastuzumab) and Biosimilar market?
2. What is the demand of the global Herceptin (Trastuzumab) and Biosimilar market?
3. What is the year over year growth of the global Herceptin (Trastuzumab) and Biosimilar market?
4. What is the production and production value of the global Herceptin (Trastuzumab) and Biosimilar market?
5. Who are the key producers in the global Herceptin (Trastuzumab) and Biosimilar market?
6. What are the growth factors driving the market demand?
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.
This report studies the global Herceptin (Trastuzumab) and Biosimilar production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Herceptin (Trastuzumab) and Biosimilar, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Herceptin (Trastuzumab) and Biosimilar that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Herceptin (Trastuzumab) and Biosimilar total production and demand, 2018-2029, (K Units)
Global Herceptin (Trastuzumab) and Biosimilar total production value, 2018-2029, (USD Million)
Global Herceptin (Trastuzumab) and Biosimilar production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Herceptin (Trastuzumab) and Biosimilar consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Herceptin (Trastuzumab) and Biosimilar domestic production, consumption, key domestic manufacturers and share
Global Herceptin (Trastuzumab) and Biosimilar production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Herceptin (Trastuzumab) and Biosimilar production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Herceptin (Trastuzumab) and Biosimilar production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Herceptin (Trastuzumab) and Biosimilar market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, Pfizer, Organon, Teva and Viatris, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Herceptin (Trastuzumab) and Biosimilar market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Herceptin (Trastuzumab) and Biosimilar Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Brand
- Biosimilar
- Breast Cancer
- Stomach Cancer
- Roche
- Amgen
- Pfizer
- Organon
- Teva
- Viatris
1. How big is the global Herceptin (Trastuzumab) and Biosimilar market?
2. What is the demand of the global Herceptin (Trastuzumab) and Biosimilar market?
3. What is the year over year growth of the global Herceptin (Trastuzumab) and Biosimilar market?
4. What is the production and production value of the global Herceptin (Trastuzumab) and Biosimilar market?
5. Who are the key producers in the global Herceptin (Trastuzumab) and Biosimilar market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Herceptin (Trastuzumab) and Biosimilar Introduction
1.2 World Herceptin (Trastuzumab) and Biosimilar Supply & Forecast
1.2.1 World Herceptin (Trastuzumab) and Biosimilar Production Value (2018 & 2022 & 2029)
1.2.2 World Herceptin (Trastuzumab) and Biosimilar Production (2018-2029)
1.2.3 World Herceptin (Trastuzumab) and Biosimilar Pricing Trends (2018-2029)
1.3 World Herceptin (Trastuzumab) and Biosimilar Production by Region (Based on Production Site)
1.3.1 World Herceptin (Trastuzumab) and Biosimilar Production Value by Region (2018-2029)
1.3.2 World Herceptin (Trastuzumab) and Biosimilar Production by Region (2018-2029)
1.3.3 World Herceptin (Trastuzumab) and Biosimilar Average Price by Region (2018-2029)
1.3.4 North America Herceptin (Trastuzumab) and Biosimilar Production (2018-2029)
1.3.5 Europe Herceptin (Trastuzumab) and Biosimilar Production (2018-2029)
1.3.6 China Herceptin (Trastuzumab) and Biosimilar Production (2018-2029)
1.3.7 Japan Herceptin (Trastuzumab) and Biosimilar Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Herceptin (Trastuzumab) and Biosimilar Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Herceptin (Trastuzumab) and Biosimilar Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Herceptin (Trastuzumab) and Biosimilar Demand (2018-2029)
2.2 World Herceptin (Trastuzumab) and Biosimilar Consumption by Region
2.2.1 World Herceptin (Trastuzumab) and Biosimilar Consumption by Region (2018-2023)
2.2.2 World Herceptin (Trastuzumab) and Biosimilar Consumption Forecast by Region (2024-2029)
2.3 United States Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029)
2.4 China Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029)
2.5 Europe Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029)
2.6 Japan Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029)
2.7 South Korea Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029)
2.8 ASEAN Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029)
2.9 India Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029)
3 WORLD HERCEPTIN (TRASTUZUMAB) AND BIOSIMILAR MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Herceptin (Trastuzumab) and Biosimilar Production Value by Manufacturer (2018-2023)
3.2 World Herceptin (Trastuzumab) and Biosimilar Production by Manufacturer (2018-2023)
3.3 World Herceptin (Trastuzumab) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Herceptin (Trastuzumab) and Biosimilar Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Herceptin (Trastuzumab) and Biosimilar Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Herceptin (Trastuzumab) and Biosimilar in 2022
3.5.3 Global Concentration Ratios (CR8) for Herceptin (Trastuzumab) and Biosimilar in 2022
3.6 Herceptin (Trastuzumab) and Biosimilar Market: Overall Company Footprint Analysis
3.6.1 Herceptin (Trastuzumab) and Biosimilar Market: Region Footprint
3.6.2 Herceptin (Trastuzumab) and Biosimilar Market: Company Product Type Footprint
3.6.3 Herceptin (Trastuzumab) and Biosimilar Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Value Comparison
4.1.1 United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Comparison
4.2.1 United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Herceptin (Trastuzumab) and Biosimilar Consumption Comparison
4.3.1 United States VS China: Herceptin (Trastuzumab) and Biosimilar Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Herceptin (Trastuzumab) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Herceptin (Trastuzumab) and Biosimilar Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Herceptin (Trastuzumab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value (2018-2023)
4.4.3 United States Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production (2018-2023)
4.5 China Based Herceptin (Trastuzumab) and Biosimilar Manufacturers and Market Share
4.5.1 China Based Herceptin (Trastuzumab) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value (2018-2023)
4.5.3 China Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production (2018-2023)
4.6 Rest of World Based Herceptin (Trastuzumab) and Biosimilar Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Herceptin (Trastuzumab) and Biosimilar Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Herceptin (Trastuzumab) and Biosimilar Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Brand
5.2.2 Biosimilar
5.3 Market Segment by Type
5.3.1 World Herceptin (Trastuzumab) and Biosimilar Production by Type (2018-2029)
5.3.2 World Herceptin (Trastuzumab) and Biosimilar Production Value by Type (2018-2029)
5.3.3 World Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Herceptin (Trastuzumab) and Biosimilar Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Breast Cancer
6.2.2 Stomach Cancer
6.3 Market Segment by Application
6.3.1 World Herceptin (Trastuzumab) and Biosimilar Production by Application (2018-2029)
6.3.2 World Herceptin (Trastuzumab) and Biosimilar Production Value by Application (2018-2029)
6.3.3 World Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Roche
7.1.1 Roche Details
7.1.2 Roche Major Business
7.1.3 Roche Herceptin (Trastuzumab) and Biosimilar Product and Services
7.1.4 Roche Herceptin (Trastuzumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Roche Recent Developments/Updates
7.1.6 Roche Competitive Strengths & Weaknesses
7.2 Amgen
7.2.1 Amgen Details
7.2.2 Amgen Major Business
7.2.3 Amgen Herceptin (Trastuzumab) and Biosimilar Product and Services
7.2.4 Amgen Herceptin (Trastuzumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Amgen Recent Developments/Updates
7.2.6 Amgen Competitive Strengths & Weaknesses
7.3 Pfizer
7.3.1 Pfizer Details
7.3.2 Pfizer Major Business
7.3.3 Pfizer Herceptin (Trastuzumab) and Biosimilar Product and Services
7.3.4 Pfizer Herceptin (Trastuzumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Pfizer Recent Developments/Updates
7.3.6 Pfizer Competitive Strengths & Weaknesses
7.4 Organon
7.4.1 Organon Details
7.4.2 Organon Major Business
7.4.3 Organon Herceptin (Trastuzumab) and Biosimilar Product and Services
7.4.4 Organon Herceptin (Trastuzumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Organon Recent Developments/Updates
7.4.6 Organon Competitive Strengths & Weaknesses
7.5 Teva
7.5.1 Teva Details
7.5.2 Teva Major Business
7.5.3 Teva Herceptin (Trastuzumab) and Biosimilar Product and Services
7.5.4 Teva Herceptin (Trastuzumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Teva Recent Developments/Updates
7.5.6 Teva Competitive Strengths & Weaknesses
7.6 Viatris
7.6.1 Viatris Details
7.6.2 Viatris Major Business
7.6.3 Viatris Herceptin (Trastuzumab) and Biosimilar Product and Services
7.6.4 Viatris Herceptin (Trastuzumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Viatris Recent Developments/Updates
7.6.6 Viatris Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Herceptin (Trastuzumab) and Biosimilar Industry Chain
8.2 Herceptin (Trastuzumab) and Biosimilar Upstream Analysis
8.2.1 Herceptin (Trastuzumab) and Biosimilar Core Raw Materials
8.2.2 Main Manufacturers of Herceptin (Trastuzumab) and Biosimilar Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Herceptin (Trastuzumab) and Biosimilar Production Mode
8.6 Herceptin (Trastuzumab) and Biosimilar Procurement Model
8.7 Herceptin (Trastuzumab) and Biosimilar Industry Sales Model and Sales Channels
8.7.1 Herceptin (Trastuzumab) and Biosimilar Sales Model
8.7.2 Herceptin (Trastuzumab) and Biosimilar Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Herceptin (Trastuzumab) and Biosimilar Introduction
1.2 World Herceptin (Trastuzumab) and Biosimilar Supply & Forecast
1.2.1 World Herceptin (Trastuzumab) and Biosimilar Production Value (2018 & 2022 & 2029)
1.2.2 World Herceptin (Trastuzumab) and Biosimilar Production (2018-2029)
1.2.3 World Herceptin (Trastuzumab) and Biosimilar Pricing Trends (2018-2029)
1.3 World Herceptin (Trastuzumab) and Biosimilar Production by Region (Based on Production Site)
1.3.1 World Herceptin (Trastuzumab) and Biosimilar Production Value by Region (2018-2029)
1.3.2 World Herceptin (Trastuzumab) and Biosimilar Production by Region (2018-2029)
1.3.3 World Herceptin (Trastuzumab) and Biosimilar Average Price by Region (2018-2029)
1.3.4 North America Herceptin (Trastuzumab) and Biosimilar Production (2018-2029)
1.3.5 Europe Herceptin (Trastuzumab) and Biosimilar Production (2018-2029)
1.3.6 China Herceptin (Trastuzumab) and Biosimilar Production (2018-2029)
1.3.7 Japan Herceptin (Trastuzumab) and Biosimilar Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Herceptin (Trastuzumab) and Biosimilar Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Herceptin (Trastuzumab) and Biosimilar Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Herceptin (Trastuzumab) and Biosimilar Demand (2018-2029)
2.2 World Herceptin (Trastuzumab) and Biosimilar Consumption by Region
2.2.1 World Herceptin (Trastuzumab) and Biosimilar Consumption by Region (2018-2023)
2.2.2 World Herceptin (Trastuzumab) and Biosimilar Consumption Forecast by Region (2024-2029)
2.3 United States Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029)
2.4 China Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029)
2.5 Europe Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029)
2.6 Japan Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029)
2.7 South Korea Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029)
2.8 ASEAN Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029)
2.9 India Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029)
3 WORLD HERCEPTIN (TRASTUZUMAB) AND BIOSIMILAR MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Herceptin (Trastuzumab) and Biosimilar Production Value by Manufacturer (2018-2023)
3.2 World Herceptin (Trastuzumab) and Biosimilar Production by Manufacturer (2018-2023)
3.3 World Herceptin (Trastuzumab) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Herceptin (Trastuzumab) and Biosimilar Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Herceptin (Trastuzumab) and Biosimilar Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Herceptin (Trastuzumab) and Biosimilar in 2022
3.5.3 Global Concentration Ratios (CR8) for Herceptin (Trastuzumab) and Biosimilar in 2022
3.6 Herceptin (Trastuzumab) and Biosimilar Market: Overall Company Footprint Analysis
3.6.1 Herceptin (Trastuzumab) and Biosimilar Market: Region Footprint
3.6.2 Herceptin (Trastuzumab) and Biosimilar Market: Company Product Type Footprint
3.6.3 Herceptin (Trastuzumab) and Biosimilar Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Value Comparison
4.1.1 United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Comparison
4.2.1 United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Herceptin (Trastuzumab) and Biosimilar Consumption Comparison
4.3.1 United States VS China: Herceptin (Trastuzumab) and Biosimilar Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Herceptin (Trastuzumab) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Herceptin (Trastuzumab) and Biosimilar Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Herceptin (Trastuzumab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value (2018-2023)
4.4.3 United States Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production (2018-2023)
4.5 China Based Herceptin (Trastuzumab) and Biosimilar Manufacturers and Market Share
4.5.1 China Based Herceptin (Trastuzumab) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value (2018-2023)
4.5.3 China Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production (2018-2023)
4.6 Rest of World Based Herceptin (Trastuzumab) and Biosimilar Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Herceptin (Trastuzumab) and Biosimilar Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Herceptin (Trastuzumab) and Biosimilar Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Brand
5.2.2 Biosimilar
5.3 Market Segment by Type
5.3.1 World Herceptin (Trastuzumab) and Biosimilar Production by Type (2018-2029)
5.3.2 World Herceptin (Trastuzumab) and Biosimilar Production Value by Type (2018-2029)
5.3.3 World Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Herceptin (Trastuzumab) and Biosimilar Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Breast Cancer
6.2.2 Stomach Cancer
6.3 Market Segment by Application
6.3.1 World Herceptin (Trastuzumab) and Biosimilar Production by Application (2018-2029)
6.3.2 World Herceptin (Trastuzumab) and Biosimilar Production Value by Application (2018-2029)
6.3.3 World Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Roche
7.1.1 Roche Details
7.1.2 Roche Major Business
7.1.3 Roche Herceptin (Trastuzumab) and Biosimilar Product and Services
7.1.4 Roche Herceptin (Trastuzumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Roche Recent Developments/Updates
7.1.6 Roche Competitive Strengths & Weaknesses
7.2 Amgen
7.2.1 Amgen Details
7.2.2 Amgen Major Business
7.2.3 Amgen Herceptin (Trastuzumab) and Biosimilar Product and Services
7.2.4 Amgen Herceptin (Trastuzumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Amgen Recent Developments/Updates
7.2.6 Amgen Competitive Strengths & Weaknesses
7.3 Pfizer
7.3.1 Pfizer Details
7.3.2 Pfizer Major Business
7.3.3 Pfizer Herceptin (Trastuzumab) and Biosimilar Product and Services
7.3.4 Pfizer Herceptin (Trastuzumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Pfizer Recent Developments/Updates
7.3.6 Pfizer Competitive Strengths & Weaknesses
7.4 Organon
7.4.1 Organon Details
7.4.2 Organon Major Business
7.4.3 Organon Herceptin (Trastuzumab) and Biosimilar Product and Services
7.4.4 Organon Herceptin (Trastuzumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.4.5 Organon Recent Developments/Updates
7.4.6 Organon Competitive Strengths & Weaknesses
7.5 Teva
7.5.1 Teva Details
7.5.2 Teva Major Business
7.5.3 Teva Herceptin (Trastuzumab) and Biosimilar Product and Services
7.5.4 Teva Herceptin (Trastuzumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.5.5 Teva Recent Developments/Updates
7.5.6 Teva Competitive Strengths & Weaknesses
7.6 Viatris
7.6.1 Viatris Details
7.6.2 Viatris Major Business
7.6.3 Viatris Herceptin (Trastuzumab) and Biosimilar Product and Services
7.6.4 Viatris Herceptin (Trastuzumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.6.5 Viatris Recent Developments/Updates
7.6.6 Viatris Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Herceptin (Trastuzumab) and Biosimilar Industry Chain
8.2 Herceptin (Trastuzumab) and Biosimilar Upstream Analysis
8.2.1 Herceptin (Trastuzumab) and Biosimilar Core Raw Materials
8.2.2 Main Manufacturers of Herceptin (Trastuzumab) and Biosimilar Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Herceptin (Trastuzumab) and Biosimilar Production Mode
8.6 Herceptin (Trastuzumab) and Biosimilar Procurement Model
8.7 Herceptin (Trastuzumab) and Biosimilar Industry Sales Model and Sales Channels
8.7.1 Herceptin (Trastuzumab) and Biosimilar Sales Model
8.7.2 Herceptin (Trastuzumab) and Biosimilar Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Herceptin (Trastuzumab) and Biosimilar Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Herceptin (Trastuzumab) and Biosimilar Production Value by Region (2018-2023) & (USD Million)
Table 3. World Herceptin (Trastuzumab) and Biosimilar Production Value by Region (2024-2029) & (USD Million)
Table 4. World Herceptin (Trastuzumab) and Biosimilar Production Value Market Share by Region (2018-2023)
Table 5. World Herceptin (Trastuzumab) and Biosimilar Production Value Market Share by Region (2024-2029)
Table 6. World Herceptin (Trastuzumab) and Biosimilar Production by Region (2018-2023) & (K Units)
Table 7. World Herceptin (Trastuzumab) and Biosimilar Production by Region (2024-2029) & (K Units)
Table 8. World Herceptin (Trastuzumab) and Biosimilar Production Market Share by Region (2018-2023)
Table 9. World Herceptin (Trastuzumab) and Biosimilar Production Market Share by Region (2024-2029)
Table 10. World Herceptin (Trastuzumab) and Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Herceptin (Trastuzumab) and Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Herceptin (Trastuzumab) and Biosimilar Major Market Trends
Table 13. World Herceptin (Trastuzumab) and Biosimilar Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Herceptin (Trastuzumab) and Biosimilar Consumption by Region (2018-2023) & (K Units)
Table 15. World Herceptin (Trastuzumab) and Biosimilar Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Herceptin (Trastuzumab) and Biosimilar Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Herceptin (Trastuzumab) and Biosimilar Producers in 2022
Table 18. World Herceptin (Trastuzumab) and Biosimilar Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Herceptin (Trastuzumab) and Biosimilar Producers in 2022
Table 20. World Herceptin (Trastuzumab) and Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Herceptin (Trastuzumab) and Biosimilar Company Evaluation Quadrant
Table 22. World Herceptin (Trastuzumab) and Biosimilar Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Herceptin (Trastuzumab) and Biosimilar Production Site of Key Manufacturer
Table 24. Herceptin (Trastuzumab) and Biosimilar Market: Company Product Type Footprint
Table 25. Herceptin (Trastuzumab) and Biosimilar Market: Company Product Application Footprint
Table 26. Herceptin (Trastuzumab) and Biosimilar Competitive Factors
Table 27. Herceptin (Trastuzumab) and Biosimilar New Entrant and Capacity Expansion Plans
Table 28. Herceptin (Trastuzumab) and Biosimilar Mergers & Acquisitions Activity
Table 29. United States VS China Herceptin (Trastuzumab) and Biosimilar Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Herceptin (Trastuzumab) and Biosimilar Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Herceptin (Trastuzumab) and Biosimilar Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Herceptin (Trastuzumab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Market Share (2018-2023)
Table 37. China Based Herceptin (Trastuzumab) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Market Share (2018-2023)
Table 42. Rest of World Based Herceptin (Trastuzumab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Market Share (2018-2023)
Table 47. World Herceptin (Trastuzumab) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Herceptin (Trastuzumab) and Biosimilar Production by Type (2018-2023) & (K Units)
Table 49. World Herceptin (Trastuzumab) and Biosimilar Production by Type (2024-2029) & (K Units)
Table 50. World Herceptin (Trastuzumab) and Biosimilar Production Value by Type (2018-2023) & (USD Million)
Table 51. World Herceptin (Trastuzumab) and Biosimilar Production Value by Type (2024-2029) & (USD Million)
Table 52. World Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Herceptin (Trastuzumab) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Herceptin (Trastuzumab) and Biosimilar Production by Application (2018-2023) & (K Units)
Table 56. World Herceptin (Trastuzumab) and Biosimilar Production by Application (2024-2029) & (K Units)
Table 57. World Herceptin (Trastuzumab) and Biosimilar Production Value by Application (2018-2023) & (USD Million)
Table 58. World Herceptin (Trastuzumab) and Biosimilar Production Value by Application (2024-2029) & (USD Million)
Table 59. World Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Roche Basic Information, Manufacturing Base and Competitors
Table 62. Roche Major Business
Table 63. Roche Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 64. Roche Herceptin (Trastuzumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Roche Recent Developments/Updates
Table 66. Roche Competitive Strengths & Weaknesses
Table 67. Amgen Basic Information, Manufacturing Base and Competitors
Table 68. Amgen Major Business
Table 69. Amgen Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 70. Amgen Herceptin (Trastuzumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Amgen Recent Developments/Updates
Table 72. Amgen Competitive Strengths & Weaknesses
Table 73. Pfizer Basic Information, Manufacturing Base and Competitors
Table 74. Pfizer Major Business
Table 75. Pfizer Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 76. Pfizer Herceptin (Trastuzumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Pfizer Recent Developments/Updates
Table 78. Pfizer Competitive Strengths & Weaknesses
Table 79. Organon Basic Information, Manufacturing Base and Competitors
Table 80. Organon Major Business
Table 81. Organon Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 82. Organon Herceptin (Trastuzumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Organon Recent Developments/Updates
Table 84. Organon Competitive Strengths & Weaknesses
Table 85. Teva Basic Information, Manufacturing Base and Competitors
Table 86. Teva Major Business
Table 87. Teva Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 88. Teva Herceptin (Trastuzumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Teva Recent Developments/Updates
Table 90. Viatris Basic Information, Manufacturing Base and Competitors
Table 91. Viatris Major Business
Table 92. Viatris Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 93. Viatris Herceptin (Trastuzumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Global Key Players of Herceptin (Trastuzumab) and Biosimilar Upstream (Raw Materials)
Table 95. Herceptin (Trastuzumab) and Biosimilar Typical Customers
Table 96. Herceptin (Trastuzumab) and Biosimilar Typical Distributors
Table 1. World Herceptin (Trastuzumab) and Biosimilar Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Herceptin (Trastuzumab) and Biosimilar Production Value by Region (2018-2023) & (USD Million)
Table 3. World Herceptin (Trastuzumab) and Biosimilar Production Value by Region (2024-2029) & (USD Million)
Table 4. World Herceptin (Trastuzumab) and Biosimilar Production Value Market Share by Region (2018-2023)
Table 5. World Herceptin (Trastuzumab) and Biosimilar Production Value Market Share by Region (2024-2029)
Table 6. World Herceptin (Trastuzumab) and Biosimilar Production by Region (2018-2023) & (K Units)
Table 7. World Herceptin (Trastuzumab) and Biosimilar Production by Region (2024-2029) & (K Units)
Table 8. World Herceptin (Trastuzumab) and Biosimilar Production Market Share by Region (2018-2023)
Table 9. World Herceptin (Trastuzumab) and Biosimilar Production Market Share by Region (2024-2029)
Table 10. World Herceptin (Trastuzumab) and Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Herceptin (Trastuzumab) and Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Herceptin (Trastuzumab) and Biosimilar Major Market Trends
Table 13. World Herceptin (Trastuzumab) and Biosimilar Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Herceptin (Trastuzumab) and Biosimilar Consumption by Region (2018-2023) & (K Units)
Table 15. World Herceptin (Trastuzumab) and Biosimilar Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Herceptin (Trastuzumab) and Biosimilar Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Herceptin (Trastuzumab) and Biosimilar Producers in 2022
Table 18. World Herceptin (Trastuzumab) and Biosimilar Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Herceptin (Trastuzumab) and Biosimilar Producers in 2022
Table 20. World Herceptin (Trastuzumab) and Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Herceptin (Trastuzumab) and Biosimilar Company Evaluation Quadrant
Table 22. World Herceptin (Trastuzumab) and Biosimilar Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Herceptin (Trastuzumab) and Biosimilar Production Site of Key Manufacturer
Table 24. Herceptin (Trastuzumab) and Biosimilar Market: Company Product Type Footprint
Table 25. Herceptin (Trastuzumab) and Biosimilar Market: Company Product Application Footprint
Table 26. Herceptin (Trastuzumab) and Biosimilar Competitive Factors
Table 27. Herceptin (Trastuzumab) and Biosimilar New Entrant and Capacity Expansion Plans
Table 28. Herceptin (Trastuzumab) and Biosimilar Mergers & Acquisitions Activity
Table 29. United States VS China Herceptin (Trastuzumab) and Biosimilar Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Herceptin (Trastuzumab) and Biosimilar Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Herceptin (Trastuzumab) and Biosimilar Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Herceptin (Trastuzumab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Market Share (2018-2023)
Table 37. China Based Herceptin (Trastuzumab) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Market Share (2018-2023)
Table 42. Rest of World Based Herceptin (Trastuzumab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Market Share (2018-2023)
Table 47. World Herceptin (Trastuzumab) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Herceptin (Trastuzumab) and Biosimilar Production by Type (2018-2023) & (K Units)
Table 49. World Herceptin (Trastuzumab) and Biosimilar Production by Type (2024-2029) & (K Units)
Table 50. World Herceptin (Trastuzumab) and Biosimilar Production Value by Type (2018-2023) & (USD Million)
Table 51. World Herceptin (Trastuzumab) and Biosimilar Production Value by Type (2024-2029) & (USD Million)
Table 52. World Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Herceptin (Trastuzumab) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Herceptin (Trastuzumab) and Biosimilar Production by Application (2018-2023) & (K Units)
Table 56. World Herceptin (Trastuzumab) and Biosimilar Production by Application (2024-2029) & (K Units)
Table 57. World Herceptin (Trastuzumab) and Biosimilar Production Value by Application (2018-2023) & (USD Million)
Table 58. World Herceptin (Trastuzumab) and Biosimilar Production Value by Application (2024-2029) & (USD Million)
Table 59. World Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Roche Basic Information, Manufacturing Base and Competitors
Table 62. Roche Major Business
Table 63. Roche Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 64. Roche Herceptin (Trastuzumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Roche Recent Developments/Updates
Table 66. Roche Competitive Strengths & Weaknesses
Table 67. Amgen Basic Information, Manufacturing Base and Competitors
Table 68. Amgen Major Business
Table 69. Amgen Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 70. Amgen Herceptin (Trastuzumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Amgen Recent Developments/Updates
Table 72. Amgen Competitive Strengths & Weaknesses
Table 73. Pfizer Basic Information, Manufacturing Base and Competitors
Table 74. Pfizer Major Business
Table 75. Pfizer Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 76. Pfizer Herceptin (Trastuzumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 77. Pfizer Recent Developments/Updates
Table 78. Pfizer Competitive Strengths & Weaknesses
Table 79. Organon Basic Information, Manufacturing Base and Competitors
Table 80. Organon Major Business
Table 81. Organon Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 82. Organon Herceptin (Trastuzumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 83. Organon Recent Developments/Updates
Table 84. Organon Competitive Strengths & Weaknesses
Table 85. Teva Basic Information, Manufacturing Base and Competitors
Table 86. Teva Major Business
Table 87. Teva Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 88. Teva Herceptin (Trastuzumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 89. Teva Recent Developments/Updates
Table 90. Viatris Basic Information, Manufacturing Base and Competitors
Table 91. Viatris Major Business
Table 92. Viatris Herceptin (Trastuzumab) and Biosimilar Product and Services
Table 93. Viatris Herceptin (Trastuzumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 94. Global Key Players of Herceptin (Trastuzumab) and Biosimilar Upstream (Raw Materials)
Table 95. Herceptin (Trastuzumab) and Biosimilar Typical Customers
Table 96. Herceptin (Trastuzumab) and Biosimilar Typical Distributors
LIST OF FIGURES
Figure 1. Herceptin (Trastuzumab) and Biosimilar Picture
Figure 2. World Herceptin (Trastuzumab) and Biosimilar Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Herceptin (Trastuzumab) and Biosimilar Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Herceptin (Trastuzumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 5. World Herceptin (Trastuzumab) and Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 6. World Herceptin (Trastuzumab) and Biosimilar Production Value Market Share by Region (2018-2029)
Figure 7. World Herceptin (Trastuzumab) and Biosimilar Production Market Share by Region (2018-2029)
Figure 8. North America Herceptin (Trastuzumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 9. Europe Herceptin (Trastuzumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 10. China Herceptin (Trastuzumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 11. Japan Herceptin (Trastuzumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 12. Herceptin (Trastuzumab) and Biosimilar Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 15. World Herceptin (Trastuzumab) and Biosimilar Consumption Market Share by Region (2018-2029)
Figure 16. United States Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 17. China Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 18. Europe Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 19. Japan Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 20. South Korea Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 22. India Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Herceptin (Trastuzumab) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Herceptin (Trastuzumab) and Biosimilar Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Herceptin (Trastuzumab) and Biosimilar Markets in 2022
Figure 26. United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Herceptin (Trastuzumab) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Market Share 2022
Figure 30. China Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Market Share 2022
Figure 32. World Herceptin (Trastuzumab) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Herceptin (Trastuzumab) and Biosimilar Production Value Market Share by Type in 2022
Figure 34. Brand
Figure 35. Biosimilar
Figure 36. World Herceptin (Trastuzumab) and Biosimilar Production Market Share by Type (2018-2029)
Figure 37. World Herceptin (Trastuzumab) and Biosimilar Production Value Market Share by Type (2018-2029)
Figure 38. World Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 39. World Herceptin (Trastuzumab) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 40. World Herceptin (Trastuzumab) and Biosimilar Production Value Market Share by Application in 2022
Figure 41. Breast Cancer
Figure 42. Stomach Cancer
Figure 43. World Herceptin (Trastuzumab) and Biosimilar Production Market Share by Application (2018-2029)
Figure 44. World Herceptin (Trastuzumab) and Biosimilar Production Value Market Share by Application (2018-2029)
Figure 45. World Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 46. Herceptin (Trastuzumab) and Biosimilar Industry Chain
Figure 47. Herceptin (Trastuzumab) and Biosimilar Procurement Model
Figure 48. Herceptin (Trastuzumab) and Biosimilar Sales Model
Figure 49. Herceptin (Trastuzumab) and Biosimilar Sales Channels, Direct Sales, and Distribution
Figure 50. Methodology
Figure 51. Research Process and Data Source
Figure 1. Herceptin (Trastuzumab) and Biosimilar Picture
Figure 2. World Herceptin (Trastuzumab) and Biosimilar Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Herceptin (Trastuzumab) and Biosimilar Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Herceptin (Trastuzumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 5. World Herceptin (Trastuzumab) and Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 6. World Herceptin (Trastuzumab) and Biosimilar Production Value Market Share by Region (2018-2029)
Figure 7. World Herceptin (Trastuzumab) and Biosimilar Production Market Share by Region (2018-2029)
Figure 8. North America Herceptin (Trastuzumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 9. Europe Herceptin (Trastuzumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 10. China Herceptin (Trastuzumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 11. Japan Herceptin (Trastuzumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 12. Herceptin (Trastuzumab) and Biosimilar Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 15. World Herceptin (Trastuzumab) and Biosimilar Consumption Market Share by Region (2018-2029)
Figure 16. United States Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 17. China Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 18. Europe Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 19. Japan Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 20. South Korea Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 22. India Herceptin (Trastuzumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Herceptin (Trastuzumab) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Herceptin (Trastuzumab) and Biosimilar Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Herceptin (Trastuzumab) and Biosimilar Markets in 2022
Figure 26. United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Herceptin (Trastuzumab) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Herceptin (Trastuzumab) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Market Share 2022
Figure 30. China Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Herceptin (Trastuzumab) and Biosimilar Production Market Share 2022
Figure 32. World Herceptin (Trastuzumab) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Herceptin (Trastuzumab) and Biosimilar Production Value Market Share by Type in 2022
Figure 34. Brand
Figure 35. Biosimilar
Figure 36. World Herceptin (Trastuzumab) and Biosimilar Production Market Share by Type (2018-2029)
Figure 37. World Herceptin (Trastuzumab) and Biosimilar Production Value Market Share by Type (2018-2029)
Figure 38. World Herceptin (Trastuzumab) and Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 39. World Herceptin (Trastuzumab) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 40. World Herceptin (Trastuzumab) and Biosimilar Production Value Market Share by Application in 2022
Figure 41. Breast Cancer
Figure 42. Stomach Cancer
Figure 43. World Herceptin (Trastuzumab) and Biosimilar Production Market Share by Application (2018-2029)
Figure 44. World Herceptin (Trastuzumab) and Biosimilar Production Value Market Share by Application (2018-2029)
Figure 45. World Herceptin (Trastuzumab) and Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 46. Herceptin (Trastuzumab) and Biosimilar Industry Chain
Figure 47. Herceptin (Trastuzumab) and Biosimilar Procurement Model
Figure 48. Herceptin (Trastuzumab) and Biosimilar Sales Model
Figure 49. Herceptin (Trastuzumab) and Biosimilar Sales Channels, Direct Sales, and Distribution
Figure 50. Methodology
Figure 51. Research Process and Data Source
